Depression Clinical Trial
Official title:
Reward and Threat Sensitivity as Mediators of Positive and Negative Affect Treatment
The purpose of this study is to evaluate the efficacy and mediators of change in Positive Affect Treatment, a psychotherapy specifically aimed at enhancing reward sensitivity in individuals with low positive affect (a core feature of anhedonia) in the context of depression or anxiety. Target enrollment is 100 male and female participants with low positive affect and depression or anxiety and impaired functioning, between the ages of 18 and 65 years, who will be randomized to either Positive Affect Treatment or Negative Affect Treatment (designed to reduce threat sensitivity). Participants will complete laboratory tests, psychiatric assessments, and self-report questionnaires as part of the study. The total length of participation is around 5 months.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | May 31, 2024 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - English-speaking - Low positive affect indexed by less than or equal to 24 on the positive affect subscale of the PANAS (i.e., PANAS-P); and scores of greater than or equal to 11 for depression, greater to or equal to 6 for anxiety, or greater to or equal to 10 for stress on the Depression, Anxiety, and Stress Scale; and scores of greater than or equal to 5 on any Sheehan Disability Scale subscale. - Willingness to refrain from starting other psychosocial or pharmacological treatments until study completion. Exclusion Criteria: - Patient report of serious medical conditions - such as history of serious, uncontrolled medical illness, or instability (including significant cardio-pulmonary disease, organic brain syndrome, seizure disorder, cerebrovascular disease, thyroid dysfunction, and diabetes) - Active suicidal ideation - Lifetime history of bipolar disorder, psychosis, cognitive impairment, or organic brain damage - Substance abuse in the last 6 months or dependence within last 12 months. - Greater than 11 cigarettes per week or nicotine equivalent - History of marijuana, cocaine or stimulant use 5-7 times/week or more before age 15 (e.g., amphetamine, cocaine, methamphetamine) - Willingness to refrain from marijuana use 1 week before laboratory assessments - Pregnancy - Bupropion, dopaminergic or neuroleptic medications use in the past 6 months - Heterocyclics and SSRIs are permitted if stabilized (3 months) and PRN benzodiazepines and beta-blockers are permitted but discouraged on laboratory assessment visits - Refusal of video/audio-taping - Prior participation in previous waves of this study |
Country | Name | City | State |
---|---|---|---|
United States | Southern Methodist University | Dallas | Texas |
United States | University of California, Los Angeles | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | Southern Methodist University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive and Negative Affect Schedule Expanded (PANAS-X) (General Dimensions Scales) | Reported positive affect (general dimensions scale positive affect) and negative affect (general dimension scale negative affect) (score range for each scale: 10-50, higher scores represent higher levels of positive affect or negative affect). | Baseline to post-treatment (16 weeks) and follow-up (20 weeks) | |
Primary | Depression Anxiety and Stress Scale (DASS-21) | Reported symptoms of depression (score range: 0-21), anxiety (score range: 0-21), and stress (score range: 0-21), higher scores indicate higher severity and frequency. | Baseline to post-treatment (16 weeks) and follow-up (20 weeks) | |
Secondary | Interviewer Anhedonia Ratings | Interviewer ratings of interest, pleasure, and motivation in hobbies/pastimes, foods/drinks, social activities (score range: 1-12), higher scores indicate lower anhedonia | Baseline, post-treatment (16 weeks) and follow-up (20 weeks) | |
Secondary | Sheehan Disability Scale (SDS) | Reported impairment due to symptoms (score range: 0-30) with higher scores indicating greater impairment. Includes reported number of days of missed school/work and number of days of reduced productivity. | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Beck Scale for Suicide Ideation | Reported suicidal ideation (score range: 0-38), higher scores indicate higher suicidality | Baseline, post-treatment (16 weeks) and follow-up (20 weeks) | |
Secondary | Positive and Negative Affect Schedule Expanded (PANAS-X) Basic Positive Emotions Scales and Serenity | Mediator: Reported positive affect (basic positive emotions scales and serenity) (score range: 19 - 95). Note: items which overlap with the general dimensions scale for positive affect (see Outcome 1) will not be included in this composite score. Excluded overlapping items include: alert, attentive, determined, enthusiastic, excited, proud, and strong. | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Effort-Expenditure for Rewards Task (EEfRT) | Mediator: behavioral effort for reward | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Monetary Incentive Task | Mediator: cardiac acceleration to anticipation of reward | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Behavioral Inhibition/Behavioral Activation (reward drive subscale) (BAS-RD) | Mediator: Reported reward sensitivity (score range: 4-16), and threat sensitivity (score range: 7-28), with higher scores indicating higher sensitivity | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Dimensional Anhedonia Rating Scale | Mediator: Reported reward desire, motivation, effort, and pleasure (score range: 0-68), with higher scores indicating higher degree of reward desire, motivation, effort, and pleasure | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Modified Attentional Dot Probe Task | Mediator: attentional engagement with positive and negative stimuli | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | International Affective Picture System Task | Mediator: cardiac response to positive stimuli | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Temporal Experience of Pleasure Scale (consummatory subscale) | Mediator: Reported reward consummatory pleasure (score range: 8-48) | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Anxiety Sensitivity Index | Mediator: Reported threat appraisal of anxiety (score range: 0-64) | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Probability and Cost Questionnaire for Social and Physical Outcomes | Mediator: Reported threat appraisal of social and physical outcomes (score range: 0-80 for each subscale), with higher scores indicating higher cost/probability estimation | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) | |
Secondary | Mental Arithmetic Task | Mediator: cardiorespiratory response to stress | Baseline, Week 5, Week 10, post-treatment (Week 16) and follow-up (Week 20) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |